Amylyx Pharmaceuticals (AMLX)

• Market cap: $1.48B
• 1 day: -6.92%
• 5 days: -5.46%
• 1 month: -18.93%
• 3 months: -5.53%
• 6 months: -6.2%
• Year to date: 16.64%
• 1 year: 163.76%
• 5 years: -26.29%
• 10 years: -26.29%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Employees: 136